News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
10,037 Results
Type
Article (246)
Company Profile (1)
Press Release (9790)
Section
Business (6360)
Career Advice (4)
Deals (806)
Drug Development (765)
Employer Resources (1)
FDA (89)
Job Trends (266)
News (7133)
Policy (203)
Tag
2027 Genetown Standard (1)
Academia (11)
Accelerated approval (2)
Allergies (1)
Alliances (117)
ALS (6)
Alzheimer's disease (36)
Antibody-drug conjugate (ADC) (4)
Approvals (102)
Artificial intelligence (4)
ASCO (4)
Autoimmune disease (5)
Automation (1)
Bankruptcy (1)
Best Places to Work (266)
Biosimilars (2)
BioSpace Insights (2)
Biotechnology (1)
Bladder cancer (14)
Breast cancer (10)
Cancer (107)
Cardiovascular disease (2)
Career advice (4)
CAR-T (4)
CDMO (2)
Cell therapy (8)
Clinical research (768)
Collaboration (6)
Compensation (7)
COVID-19 (23)
CRISPR (2)
Cystic fibrosis (1)
Data (173)
Denatured (1)
Depression (1)
Dermatology (3)
Diabetes (11)
Diagnostics (115)
Digital health (1)
Drug discovery (2)
Drug pricing (3)
Duchenne muscular dystrophy (6)
Earnings (7111)
Editorial (1)
Events (412)
FDA (231)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (11)
Gene editing (4)
Generative AI (1)
Gene therapy (6)
GLP-1 (26)
Government (24)
Guidances (99)
Healthcare (309)
Huntington's disease (4)
IgA nephropathy (5)
Immunology and inflammation (3)
Immuno-oncology (2)
Indications (3)
Infectious disease (25)
Inflammatory bowel disease (7)
Inflation Reduction Act (1)
Intellectual property (6)
IPO (738)
Job creations (18)
Job search strategy (4)
Kidney cancer (1)
Labor market (3)
Layoffs (4)
Legal (33)
Liver cancer (4)
Lung cancer (20)
Lymphoma (11)
Machine learning (1)
Manufacturing (10)
MASH (5)
Medical device (317)
Medtech (324)
Mergers & acquisitions (78)
Metabolic disorders (36)
mRNA (1)
Multiple sclerosis (2)
Netherlands (2)
Neurodegenerative disease (5)
Neuropsychiatric disorders (1)
Neuroscience (61)
NextGen: Class of 2026 (66)
Non-profit (20)
Obesity (19)
Opinion (3)
Ovarian cancer (3)
Pain (4)
Pancreatic cancer (4)
Parkinson's disease (7)
Patents (4)
Peanut (1)
People (80)
Pharmacy benefit managers (1)
Phase 1 (125)
Phase 2 (286)
Phase 3 (428)
Pipeline (586)
Policy (1)
Postmarket research (21)
Preclinical (23)
Press Release (1)
Prostate cancer (2)
Radiopharmaceuticals (5)
Rare diseases (16)
Real estate (13)
Regulatory (203)
Reports (2)
Research institute (9)
RSV (1)
Schizophrenia (2)
Sickle cell disease (3)
Spinal muscular atrophy (1)
Startups (13)
Supply chain (2)
The Weekly (1)
Vaccines (14)
Venture capital (1)
Weight loss (19)
Women's health (4)
Date
Today (3)
Last 7 days (9)
Last 30 days (27)
Last 365 days (738)
2026 (556)
2025 (743)
2024 (841)
2023 (949)
2022 (1110)
2021 (1040)
2020 (925)
2019 (617)
2018 (501)
2017 (396)
2016 (189)
2015 (279)
2014 (191)
2013 (105)
2012 (153)
2011 (202)
2010 (153)
Location
Africa (6)
Alabama (2)
Alaska (1)
Arizona (6)
Asia (634)
Australia (35)
California (327)
Canada (84)
China (21)
Colorado (25)
Connecticut (23)
Delaware (32)
Europe (1256)
Florida (60)
Georgia (18)
Illinois (42)
India (1)
Indiana (34)
Japan (22)
Kansas (3)
Kentucky (4)
Louisiana (6)
Maryland (34)
Massachusetts (261)
Michigan (9)
Minnesota (17)
Missouri (5)
Nevada (3)
New Hampshire (2)
New Jersey (141)
New York (88)
North Carolina (68)
Northern California (184)
Ohio (14)
Oregon (2)
Pennsylvania (63)
South America (15)
Southern California (123)
Tennessee (8)
Texas (51)
United States (1365)
Utah (23)
Virginia (3)
Washington D.C. (2)
Washington State (33)
Wisconsin (5)
10,037 Results for "156".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
U.S. Life Science Tools Market Size to Hit USD 156.51 Billion by 2034
June 13, 2025
·
1 min read
Press Releases
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
November 13, 2025
·
11 min read
Press Releases
Sickle Cell Disease Treatment Market is Rising Rapidly with 15.6% CAGR by 2032
May 12, 2025
·
1 min read
BioCapital
U.S. Army Reserve Awards SAIC $156 Million Contract for IT Service Management
Science Applications International Corp. has been awarded a $156 million contract to provide system support to the U.S. Army Reserve Command through their United States Army Reserve Command Information Technology Support Services contract.
January 11, 2024
·
4 min read
Press Releases
Pharmaceutical Excipients Market Size Worth USD 15.6 Billion by 2034 Driven by Demand for Advanced Drug Delivery and Rising Chronic Disease
July 22, 2025
·
1 min read
Press Releases
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production
August 8, 2024
·
5 min read
Hemodialysis And Peritoneal Dialysis Market Size to Hit USD 156.63 Bn by 2030
According to Nova one advisor, the global Hemodialysis and Peritoneal Dialysis market was valued at USD 88.20 billion in 2021 and it is expected to hit around USD 156.63 billion by 2030 with a CAGR of 6.65% during the forecast period 2022 to 2030.
September 23, 2022
·
11 min read
Plasmid DNA Manufacturing Market Size To Hold USD 2.156 Mn By 2030
The global plasmid DNA manufacturing market size accounted for USD 446.13 million in 2022 and is expected to hold USD 2.156 million by 2030 with a CAGR of 21.7%. from 2022 to 2030
December 1, 2022
·
8 min read
Deals
ArriVent Biopharma Seeks to Net Over $156M Potentially in IPO
With initial public offering activity continuing to gain momentum in early 2024, ArriVent Biopharma in a Monday SEC filing laid out the company’s plans to go public.
January 22, 2024
·
2 min read
·
Tyler Patchen
Drug Development
ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer
ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has been dosed in the single-arm Phase 1b trial of IM156 in combination with gemcitabine and nab-paclitaxel as frontline therapy in patients with advanced pancreatic cancer.
November 17, 2022
·
3 min read
1 of 1,004
Next
